SCHEMBL23780256

SCHEMBL23780256

CCCCC(=O)n1nnc2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.62
HPGD P15428 3/20 0.62
HSD17B10 Q99714 2/20 0.62
MAPT P10636 2/20 0.62
ALOX15 P16050 1/20 0.62
ASAH1 Q13510 1/20 0.61
GAA P10253 7/20 0.59
MGAM O43451 6/20 0.59
AMY1A P0DUB6 6/20 0.59
SI P14410 6/20 0.59
MGAM2 Q2M2H8 6/20 0.59
LMNA P02545 2/20 0.56
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
SLC9A1 P19634 5/20 0.53
F2 P00734 2/20 0.53
HTT P42858 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MITF O75030 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535030 0.95 ASAH1 (0.64) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL535094 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL5793440 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL534984 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL534899 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL18206302 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL535029 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL337266 0.94 ASAH1 (0.66) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL535388 0.91 KMT2A (0.59) KMT2AHPGDHSD17B10MAPTALOX15
SCHEMBL534954 0.87 ASAH1 (0.58) KMT2AHPGDHSD17B10MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479579-B2 Therapeutic compounds and methods REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2022-10-25 US disclosed
US-11479579-B2 Therapeutic compounds and methods REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2022-10-25 US disclosed
US-20210277055-A1 THERAPEUTIC COMPOUNDS AND METHODS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-09-09 US disclosed
US-20210277055-A1 THERAPEUTIC COMPOUNDS AND METHODS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-09-09 US disclosed
CN-101384674-B Colored metallic pigment, process for producing the same, and coating composition and cosmetic preparation comprising said colored metallic pigment TOYO ALUMINIUM KABUSHIKI KAISHA (JP) 2011-12-28 CN disclosed
CN-101384674-A Colored metallic pigment, process for producing the same, and coating composition and cosmetic preparation comprising said colored metallic pigment TOYO ALUMINIUM KK (JP) 2009-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479579-B2 Therapeutic compounds and methods SNCA, PARK7, PSEN2 KMT2A 4463/4885HPGD 1054/4885HSD17B10 1086/4885
US-20210277055-A1 THERAPEUTIC COMPOUNDS AND METHODS SNCA, PARK7, PSEN2 KMT2A 4463/4885HPGD 1054/4885HSD17B10 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.